Canine
Update (June 15, 2026): Capromorelin (Entyce) Field Effectiveness — 244 Dogs, 36-58% Food Intake Increase
TL;DR. A field effectiveness study in 244 client-owned dogs found capromorelin (Entyce) produced mean food intake increases of 36 to 58% in pivotal dose-finding work, with 177 dogs in the effectiveness analysis confirming real-world clinical outcomes.
What just dropped
- Pivotal dose-finding study (https://pmc.ncbi.nlm.nih.gov/articles/PMC5217407/): mean increases in food intake ranging from 36 to 58% in dogs receiving capromorelin, with significant increases across dose groups
- Field effectiveness study (https://pmc.ncbi.nlm.nih.gov/articles/PMC5115193/): a total of 244 client-owned dogs were enrolled; 177 cases were included in the effectiveness analysis, confirming capromorelin efficacy in a real-world clinical population
Context
Capromorelin (Entyce; Elanco) is the only FDA-approved appetite stimulant for dogs, indicated for management of weight loss and stimulation of appetite. The clinical development program included both controlled dose-finding studies and a real-world client-owned dog field effectiveness study.
The dose-finding studies (Zollers et al.) established that capromorelin produced mean food intake increases of 36 to 58% across dose groups in dogs, with significant differences from placebo. The client-owned dog field effectiveness study enrolled 244 dogs across multiple clinical sites, with 177 dogs comprising the effectiveness analysis. This real-world dataset is important because the enrolled population reflects typical practice -- dogs with diverse underlying conditions causing reduced appetite, not the controlled uniform populations of phase 1 studies.
Together, these datasets confirm that the food intake and appetite benefits seen in controlled conditions translate to the heterogeneous client-owned dog population seen in everyday clinical practice.
What this changes in capromorelin (Entyce) for appetite stimulation in dogs (https://www.thevoyage.ai/forvets/knowledge/capromorelin-canine-appetite-stimulant)
The field effectiveness data (n=244 enrolled; n=177 effectiveness analysis) adds real-world clinical practice context alongside the controlled trial evidence, reinforcing confidence in capromorelin's generalizability beyond the pivotal study population.
Voyage Clinical Desk
From clinical question to SOAP draft -- cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.
Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=update-2026-06-15-capromorelin-entyce-field-effectiveness-dogs
References
- Zollers B et al. 2017. Capromorelin dose-finding study in dogs (food intake). PMC5217407. https://pmc.ncbi.nlm.nih.gov/articles/PMC5217407/
- Wofford JA et al. 2017. Field effectiveness study of capromorelin in client-owned dogs (n=244). PMC5115193. https://pmc.ncbi.nlm.nih.gov/articles/PMC5115193/
Related reads
References
More clinical updates
Update (June 15, 2026): Maropitant Reduces Vomiting in CKD Cats Without Impairing Kidney Function Markers
A prospective study found maropitant significantly reduced vomiting in CKD cats while kidney function parameters stayed stable.
Read →Update (June 15, 2026): Mirtazapine Transdermal (Mirataz) as Appetite Stimulant and Antiemetic in Cats
Mirataz combines a +3.9% vs +0.4% placebo weight gain with documented antiemetic properties, making it a dual-action option in CKD and oncology cats.
Read →Update (June 15, 2026): Gabapentin Sedation in Cats — ~40% Ataxia Rate Resolves Within 8 Hours
Van Haaften 2017: ~40% of cats given pre-visit gabapentin were wobbly at exam, all resolving within 8 hours — key data for administration timing and client counseling.
Read →Update (June 15, 2026): Long-Term Telmisartan for Hypertension in Cats — Noninferior to Benazepril, Sustained BP Control
Telmisartan is noninferior to benazepril for proteinuria (Sent 2015) and demonstrates sustained blood pressure control in long-term hypertension studies in cats.
Read →